Wallace S L, Singer J Z
Department of Medicine, State University of New York Health Sciences Center, Brooklyn.
J Rheumatol. 1988 Mar;15(3):495-9.
Published experiences with severe toxicity with intravenous colchicine have been reviewed. All reported cases reflect inappropriate use of the drug. Therapeutic rules for colchicine have been derived from this information: (1) Single intravenous doses should not exceed 2-3 mg, and cumulative total doses for an attack should not be more than 4-5 mg. (2) Patients should receive no more colchicine by any route for 7 days. (3) Colchicine doses must be reduced in the presence of renal or hepatic disease, and in the older patient with apparently normal renal function. (4) Intravenous colchicine doses should be half the size of oral ones. (5) Absolute contraindications to intravenous colchicine therapy for acute gout include combined renal and hepatic disease, creatinine clearances below 10 cc/min, and extrahepatic biliary obstruction.
已对静脉注射秋水仙碱导致严重毒性的已发表经验进行了综述。所有报告的病例均反映出该药物的使用不当。基于这些信息得出了秋水仙碱的治疗规则:(1)单次静脉注射剂量不应超过2 - 3毫克,一次发作的累积总剂量不应超过4 - 5毫克。(2)患者在7天内不应通过任何途径接受更多秋水仙碱。(3)在存在肾脏或肝脏疾病时,以及在肾功能看似正常的老年患者中,秋水仙碱剂量必须减少。(4)静脉注射秋水仙碱的剂量应为口服剂量的一半。(5)急性痛风静脉注射秋水仙碱治疗的绝对禁忌证包括合并肝肾疾病、肌酐清除率低于10毫升/分钟以及肝外胆管梗阻。